Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma by Levesque, N. et al.
HIGH-DOSE INTERFERON ALFA-2B IN MALIGNANT MELANOMA
CURRENT ONCOLOGY—VOLUME 15, NUMBER 1
36
Copyright © 2008 Multimed Inc.
ABSTRACT
The goal of the 1-year observational, multicentre,
open-label study reported here was to identify fac-
tors influencing adherence to high-dose interferon
alfa-2b adjuvant therapy in patients at high risk of
recurrence following surgical excision of malignant
melanoma. The study was carried out in 23 tertiary-
care centres across Canada.
The 225 patients enrolled in the study all had ma-
lignant melanoma that was surgically excised and that
required adjuvant treatment with interferon alfa-2b.
Of these patients, 64% were men. Mean age was
51.7 years. All patients received interferon alfa-2b
treatment during a 4-week induction phase
(20 MU/m 2 intravenously 5 days per week) followed
by a 48-week maintenance phase (10 MU/m2 subcu-
taneously 3 days per week).
Oncology nurses reviewed side-effect management
with the patients before the induction and maintenance
phases. Patients were provided with daily diaries, com-
prehensive educational materials, and ongoing nurs-
ing support. Data on side effects and discontinuations
were obtained from patient interviews and diaries.
The main outcome measurements were related
to treatment discontinuation: rate, timing, reason, and
prevention. Of the 225 patients, 75 (33.3%) discon-
tinued interferon during the induction phase, and 58
(25.8%) discontinued during the maintenance phase.
The main reasons for discontinuation were adverse
events (58%) and disease progression (26%). Patients
with a daily fluid intake greater than 1.5 L were more
likely to complete therapy than were those with an
intake less than 1.5 L (64% vs. 36%, p < 0.0001).
Of 225 patients enrolled in the interferon alfa-2b
health management program, 41% completed the
1-year treatment course. Higher fluid intake (>1.5 L
daily) was associated with increased adherence to
therapy.
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1. INTRODUCTION
In Canada, an estimated 4500 people are diagnosed
with melanoma annually. Melanoma ranks as the 7th
most frequently diagnosed cancer among Canadian
men and the 8th among Canadian women, with an
age-standardized incidence of 9–23 cases per
100,000 1. Malignant melanoma accounts for an es-
timated 4% of skin cancer cases, but it represents more
than 79% of all skin cancer deaths 2. The incidence
of melanoma is reported to be increasing at a rate of
2% annually 3.
Interferons are cytokines with a range of biologic
effects, including antiproliferative and antiviral ac-
tivity. In the clinical setting, interferon alfa-2b
(Intron A: Schering–Plough, Kenilworth, NJ, U.S.A.)
is indicated for the treatment of malignant melanoma,
hairy cell leukemia, follicular lymphoma, chronic
myelogenous leukemia, multiple myeloma, condylo-
mata acuminata, chronic hepatitis B and C, and AIDS-
related Kaposi sarcoma 4. Interferon alfa-2b is the
only adjuvant therapy that has been shown to increase
survival in high-risk melanoma patients; it is currently
being investigated as neoadjuvant therapy 5,6.
The Eastern Cooperative Oncology Group (ECOG)
trial 1684 randomized 287 patients with high-risk
resected cutaneous melanoma to a maximum toler-
ated dose of interferon alfa-2b 20 MU/m2 intrave-
nously 5 days per week for 4 weeks, followed by
10 MU/m2 subcutaneously 3 days per week for
48 weeks, or to observation 7. As compared with ob-
servation, adjuvant treatment was associated with
significant prolongation of disease-free survival to
1.7 years from 1 year and an increase in median over-
all survival to 3.8 years from 2.8 years during the
median follow-up period of 6.9 years. Additional
cooperative group studies also demonstrated signifi-
cant improvements in relapse-free survival (two stud-
ies) and overall survival (one study) with high-dose
interferon alfa-2b 5,8.
However, treatment with recombinant interferon
alfa-2b is associated with significant side effects and
is often poorly tolerated by patients. Medication-
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related side effects can occur throughout the course
of treatment (Figure 1), possibly leading to early dis-
continuation of therapy or suboptimal drug exposure.
The most common drug-related adverse effects are
chronic fatigue, myelosuppression, elevated liver
enzymes, and neurologic symptoms. Depression or
other psychiatric symptoms may also affect quality
of life and may further contribute to poor adherence
to the regimen 9–11. Dose modifications are often re-
quired, although delivery of 80% or more of the
scheduled dose can still be achieved in most patients 7.
Maintaining an adequate dose and duration of
interferon alfa-2b therapy appears to be crucial to
success of the therapy. Recent data have suggested
that the treatment benefits of adjuvant high-dose in-
terferon alfa-2b may be dose-dependent 12. Continu-
ous treatment at dosages greater than 10 MU daily
has also been reported to be required to achieve a
clinical benefit 13.
Patients have been shown to value recurrence-
free survival more highly than severe interferon tox-
icity 14. However, treatment discontinuation is a
frequent occurrence, and little is known about pa-
tient attitudes and behaviours that might influence
early cessation of treatment 15.
Ongoing nursing support appears to be one fac-
tor that is crucial to the success of interferon alfa-2b
therapy for melanoma. An analysis of nursing issues
arising from the ECOG 1684 trial identified the impor-
tant roles of accurate nursing assessments and ongo-
ing interventions in maintaining patients on therapy.
With nursing intervention, 74% of non-relapsing pa-
tients were able to complete the 1-year course of in-
terferon alfa-2b treatment 16.
To investigate possible patient factors influenc-
ing treatment discontinuation, the Intron A Health
Management Program was initiated as a structured
program of nurse counselling and support. It was
hypothesized that close monitoring and frequent fol-
low-ups would help nurses to identify factors that
might be contributing to early discontinuation of in-
terferon alfa-2b regimen by patients during the
52 weeks of therapy.
2. PATIENTS AND METHODS
2.1 Study Objectives
The Intron A Health Management Program was ini-
tiated to identify factors influencing adherence to
high-dose interferon alfa-2b adjuvant therapy in pa-
tients at high risk of recurrence following surgical
resection of their malignant melanoma.
2.2 Study Design
Consecutive patients with malignant melanoma who
met the inclusion criteria were eligible for enrolment
in the 1-year open-label study.
2.3 Sample and Setting
Adult patients who had received prior surgical treat-
ment for malignant melanoma and who were candi-
dates for adjuvant interferon treatment were eligible
for inclusion in the study. Subjects were enrolled at
23 Canadian tertiary-care centres. Most of the pa-
tients came from the Canadian provinces of Ontario
(48%), Alberta (18%), Quebec (11.0%), and British
Columbia (10%). All subjects were enrolled between
March 2001 and September 2004.
2.4 Treatment
All subjects received interferon alfa-2b (Intron A).
Adjuvant treatment was initiated within 56 days after
surgery. The scheduled dose of interferon alfa-2b was
20 MU/m2 administered intravenously 5 days per
week during a 4-week induction phase, followed by
10 MU/m2 administered subcutaneously 3 times per
week during a 48-week maintenance phase.
2.5 Evaluations
At study entry, a physician reviewed the course of
the interferon treatment, the potential adverse events,
side effects management, and reimbursement issues
with every patient. Patients were provided with a
contact number to report medication side effects.
Oncology nurses provided patients with educational
materials, including a video.
At the start of the 48-week maintenance phase
(week 5), patients were asked if they had reviewed
the educational materials. In preparation for self-ad-
ministration at home, the physician instructed patients
on the proper use of interferon alfa-2b and either ad-
ministered the first injection or observed the patient’s
self-injection. Nurses provided patients with a daily
diary and instructed them to record the site of injec-
tion, use of concomitant medications, and daily fluid
intake.
The injection sites, treatment adherence, and fluid
intake were recorded from patient diary entries and
FIGURE 1 Time of occurrence of interferon-related side effects
during the course of treatment (adapted, with permission, from
Kirkwood et al., 2002 9).HIGH-DOSE INTERFERON ALFA-2B IN MALIGNANT MELANOMA
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from patient contacts during scheduled visits or by
telephone. During the induction phase, 4 follow-up
visits were scheduled, and during the maintenance
phase, 11 visits. During the maintenance phase, pa-
tient contacts to capture data and provide support were
performed mainly by the oncology nurses. The chief
research variables were the drug discontinuation rate,
timing of discontinuation, reason for discontinuation,
and variables that affected compliance with therapy.
3. RESULTS
3.1 Demographics
A total of 225 patients with malignant melanoma re-
quiring adjuvant treatment with interferon alfa-2b
were analyzed. Almost two thirds of the study popu-
lation (64%) were men. Mean age at study entry was
51.7 years. Mean body weight was 89.8 kg for men
and 73.6 kg for women.
3.2 Medication Use
During self-administration of the interferon alfa-2b
in the 48-week maintenance phase, patients received
a mean dose of 9.2 MU/m2 per injection. Most pa-
tients (94.8%) used a multidose pen format rather than
a premixed solution (4.0%) or lyophilized powder
(1.1%). The preferred injection sites as recorded in
the patient diaries were the abdomen (36.0%), right
leg (22.5%), left leg (21.7%), left arm (9.7%), and
right arm (9.1%).
3.3 Contacts with Health Professionals
Patients had a mean of 9.8 contacts, defined as a clinic
visit or telephone follow-up, with a physician or
nurse. Most contacts were clinic visits (86.4% vs.
13.6% telephone calls). Considering all contacts,
64.1% of patients completed their diary every day,
and 91.5% were adherent with the treatment regimen.
3.4 Fluid Intake
The average quantity of fluid consumed daily by the
patients was determined to be 1.70 L. Two thirds of
the patients consumed more than 1.5 L of fluids daily.
The most common beverages were water (54.2%),
juice (21.6%), tea (6.2%), and milk (4.0%). Absten-
tion from alcohol consumption was reported by
96.4% of the patients.
The Health Management Program identified that
patients with a daily fluid intake greater than 1.5 L
were more likely to complete therapy than were those
with a daily fluid intake less than 1.5 L (64% vs. 36%,
p < 0.0001, Figure 2). The beneficial impact of hy-
dration was observed during the induction and main-
tenance phases alike. Patients with a daily fluid intake
greater than 1.5 L stayed on therapy longer than did
those with a fluid intake less than 1.5 L (mean:
39.5 weeks vs. 25.6 weeks; p < 0.0001).
3.5 Therapy Discontinuation
During the 52-week treatment period, 59% of patients
discontinued therapy: 75 of 225 patients (33.3%) dis-
continued during the induction phase, and 58 (25.8%)
discontinued during the maintenance phase (Fig-
ure 3). The mean duration of treatment for patients
who discontinued therapy was 18.3 weeks. If discon-
tinuations attributable to disease progression or death
are omitted, 51% of patients completed the full year
of therapy: 25% discontinued during the induction
phase, and 30% of the remainder did not complete
maintenance therapy.
The most common reasons for discontinuation at
any time during therapy (Table I) were adverse events
(58%) and treatment failure (26%). During the study,
4 disease-related deaths (2.7%) occurred, and 3 pa-
tients (2.0%) were lost to follow-up.
FIGURE 3 Discontinuations occurring during the induction and
maintenance phases of a 1-year course of treatment with interferon
alfa-2b.
*225 of the total 251 patients had completed their end-of-study visit at the time of analysis.
FIGURE 2 Treatment adherence among patients with high (>1.5 L)
and low (<1.5 L) daily fluid intake during a 1-year course of
interferon alfa-2b.LEVESQUE et al.
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The adverse events most frequently cited as lead-
ing to discontinuation of therapy were asthenia, nau-
sea and vomiting, liver function abnormalities,
anorexia, depression, and myalgia.
3.6 Continuation
Although the discontinuation rate was high, one third
of discontinuations occurred during the 4-week in-
duction phase. Thereafter, with ongoing nursing sup-
port, 92 of the 150 patients who started the 48-week
maintenance phase (61.3%) were able to complete
the course of treatment.
3.7 Non-adherence
Of the 92 patients who completed 1 year of therapy,
93% were adherent to the regimen more than 80% of
the time. Men were more likely to be adherent than
were women (p = 0.043). The first episode of non-
adherence occurred more often during the induction
phase (72.9%) than during the maintenance phase
(33.6%). Overall, patients completed a mean of
11.6 weeks of treatment before their first episode of
non-adherence. During the induction phase, non-ad-
herence most commonly occurred in weeks 3 and 4;
during the maintenance phase, it occurred most often
in weeks 24 and 25.
3.8 Dose Change
Of the 225 study patients, 142 (63.1%) required a
change in their dose of interferon alfa-2b. Dose
changes most commonly occurred during the induc-
tion phase (78.2% vs. 21.8% in the maintenance
phase). The adverse events that most commonly led
to a change in dose were liver enzyme changes (43%
of patients), neutropenia (21%), asthenia (10%), an-
orexia (6%), and nausea (4%). A dose change during
the induction phase improved the patients’ likelihood
of completing the course of therapy (p < 0.01).
3.9 Adverse Events
Of all 225 patients, 207 (92%) reported at least
1 adverse event. Among patients reporting an adverse
event, the mean number of events was 4.5 per pa-
tient. The adverse events that most frequently led to
therapy discontinuation (Table II) were asthenia
(20%), nausea (13%), liver function abnormalities
(11%), and anorexia (9%). Liver function abnormali-
ties occurred in 2.3% of the patients, and elevations
in hepatic enzymes, in 2.2%.
At least 1 serious adverse event possibly related
to the study medication occurred in 56 patients
(24.9%). Serious adverse events included neutrope-
nia (n = 9), elevation in hepatic enzymes (alanine
aminotransferase, gamma-glutamyl transferase, serum
glutamic oxaloacetic transaminase; n = 6), hemato-
logic abnormalities (n = 5), and depression (n = 2).
4. CONCLUSIONS
Interferons used in the treatment of various cancers,
including malignant melanoma, are well known to
cause a range of side effects that can compromise the
success of treatment. In the present study, excluding
patients who progressed or died, only 49% of pa-
tients completed 1 year of therapy. That rate is sig-
nificantly lower than the completion rates reported
in earlier studies by Kirkwood et al. (74%–90%) 7,8,
highlighting the difference between controlled clini-
cal trials and the clinical practice setting. However,
oncology nurses can play a key role in patient fol-
low-up and support and can have a significant effect
on patient adherence to therapy.
The Health Management Program of nurse coun-
selling and support observed that patients with greater
daily fluid intake (>1.5 L) were significantly more
likely to continue on a 52-week regimen of interferon
alfa-2b therapy. Adequate hydration was also signifi-
cantly correlated with a longer average duration of
therapy. That finding may be partly attributable to
the fact that patients who feel well may be more likely
to drink more fluids. A decline in fluid intake could
predict the emergence of side effects in some patients,
although that hypothesis requires further study. How-
ever, the magnitude of the difference in compliance
observed between patients with greater and lesser
TABLE II Adverse events leading to therapy discontinuation in pa-
tients (n = 134) with resected malignant melanoma taking inter-
feron alfa-2b
Adverse event (%)
Asthenia 20
Nausea 13
Liver function abnormalities 11
Anorexia 9
Headache 7
Depression 7
Malaise 4
Neutropenia 4
Other 25
TABLE I Reasons for therapy discontinuation during a 1-year course
of treatment with interferon alfa-2b in patients (n = 225) with
resected malignant melanoma
Reason (%)
Adverse events 58
Disease progression 26
Non-compliance 4
Death 3
Lost to follow-up 2
Other 7HIGH-DOSE INTERFERON ALFA-2B IN MALIGNANT MELANOMA
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fluid intakes suggests that fluid intake was unlikely
to be only a surrogate for well-being. A follow-up
study, the Health Management Program II, will fur-
ther investigate the correlation between hydration
(oral and intravenous) and compliance. Other fac-
tors that may potentially influence compliance, such
as concomitant medication use and social supports,
will also be examined.
The Health Management Program reported here
also demonstrated that dose adjustments improved
the likelihood that patients would continue on inter-
feron alfa-2b therapy, a finding that has been reported
previously 17.
For patients entering the maintenance phase, most
therapy discontinuations were the result of adverse
events. However, many adverse events might be
managed successfully with adequate hydration, dose
reductions, and nursing or other interventions.
In conclusion, the Melanoma Health Management
Program of nurse counselling and support highlighted
the need to emphasize the importance of adequate hy-
dration and to devise, in consultation with patients,
effective strategies to manage adverse events to en-
sure that patients maximized their adherence to therapy.
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